Journal article
Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis
SE Murthy, F Chatterjee, A Crook, R Dawson, C Mendel, ME Murphy, SR Murray, AJ Nunn, PPJ Phillips, KP Singh, TD McHugh, SH Gillespie, A Diacon, M Hanekom, A Venter, K Narunsky, B Mtafya, NE Ntinginya, A Rachow, E Amukoye Show all
BMC Medicine | Published : 2018
Abstract
Background: Chest radiographs are used for diagnosis and severity assessment in tuberculosis (TB). The extent of disease as determined by smear grade and cavitation as a binary measure can predict 2-month smear results, but little has been done to determine whether radiological severity reflects the bacterial burden at diagnosis. Methods: Pre-treatment chest x-rays from 1837 participants with smear-positive pulmonary TB enrolled into the REMoxTB trial (Gillespie et al., N Engl J Med 371:1577-87, 2014) were retrospectively reviewed. Two clinicians blinded to clinical details using the Ralph scoring system performed separate readings. An independent reader reviewed discrepant results for quali..
View full abstractRelated Projects (1)
Grants
Awarded by Bayer HealthCare
Funding Acknowledgements
Supported by the Global Alliance for TB Drug Development with support from the Bill and Melinda Gates Foundation, the European and Developing Countries Clinical Trials Partnership (grant IP. 2007.32011.011), US Agency for International Development, UK Department for International Development, Directorate General for International Cooperation of the Netherlands, Irish Aid, Australia Department of Foreign Affairs and Trade, and National Institutes of Health, AIDS Clinical Trials Group. Further, it was supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID) (UM1AI068634, UM1 AI068636, and UM1AI106701), NIAID grants to the University of KwaZulu Natal, South Africa, AIDS Clinical Trials Group (ACTG) site 31422 (1U01AI069469), to the Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, South Africa, ACTG site 12301 (1U01AI069453), and to the Durban International Clinical Trials Unit, South Africa, ACTG site 11201 (1U01AI069426), as well as by Bayer Healthcare through the donation of moxifloxacin and Sanofi through the donation of rifampin. Andrew Nunn's salary came through core funding MC_UU_12023/27 Tuberculosis Treatment Trials.